Payment overview · 2025
General Payments
$1,786.92
30 reported records · 12 companies
Healthcare provider profile · identity verified
Eileen Fermin, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · SEBASTIAN, FL · NPI 1265553325
Verified facts
What the public records show
CMS Open Payments records show Eileen Fermin, MD received $1,786.92 in general payments during 2025 across 30 reported records.
Boston Scientific Corporation accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $881.49 | 49.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $201.70 | 11.3% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $160.47 | 9.0% | 4 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $156.65 | 8.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.31 | 3.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.92 | 2.7% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $34.74 | 1.9% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $31.52 | 1.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.66 | 1.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.65 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.81 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,450.54 | 29 |
| Travel and Lodging | $336.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $662.89 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $218.60 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $160.47 | 4 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $156.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $150.23 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.31 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.47 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.92 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $34.74 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.66 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 606 | 177 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 554 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 153 |
| Lisinopril | Lisinopril | 302 | 95 |
| Omeprazole | Omeprazole | 290 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 76 |
| Alprazolam | Alprazolam | 231 | 48 |
| Gabapentin | Gabapentin | 230 | 64 |
| Losartan Potassium | Losartan Potassium | 225 | 73 |
| Simvastatin | Simvastatin | 211 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 62 |
| Metformin Hcl | Metformin Hcl | 189 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 65 |
| Meloxicam | Meloxicam | 172 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 49 |
| Sertraline Hcl | Sertraline Hcl | 138 | 42 |
| Buspirone Hcl | Buspirone Hcl | 137 | 48 |
| Trazodone Hcl | Trazodone Hcl | 131 | 49 |
| Alendronate Sodium | Alendronate Sodium | 130 | 44 |
| Ipratropium Bromide | Ipratropium Bromide | 123 | 62 |
| Montelukast Sodium | Montelukast Sodium | 104 | 34 |
| Atenolol | Atenolol | 103 | 30 |
| Lorazepam | Lorazepam | 102 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 27 |
| Furosemide | Furosemide | 98 | 32 |
| Prednisone | Prednisone | 98 | 75 |
| Eliquis | Apixaban | 95 | 24 |
| Temazepam | Temazepam | 95 | 15 |
| Famotidine | Famotidine | 85 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 22 |
| Clonazepam | Clonazepam | 81 | 16 |
| Eszopiclone | Eszopiclone | 78 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 24 |
| Mounjaro | Tirzepatide | 78 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 23 |
| Celecoxib | Celecoxib | 75 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 31 |
| Tramadol Hcl | Tramadol Hcl | 73 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 56 |
| Ozempic | Semaglutide | 71 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 16 |
| Synthroid | Levothyroxine Sodium | 68 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 22 |
| Allopurinol | Allopurinol | 63 | 17 |
| Ezetimibe | Ezetimibe | 58 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 15 |
| Glimepiride | Glimepiride | 53 | 16 |
| Azithromycin | Azithromycin | 51 | 44 |
| Valsartan | Valsartan | 50 | 16 |
| Bupropion Xl | Bupropion Hcl | 49 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | 12 |
| Potassium Chloride | Potassium Chloride | 49 | 15 |
| Glipizide | Glipizide | 44 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 43 | 24 |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Estradiol | Estradiol | 42 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 42 | 14 |
| Baclofen | Baclofen | 40 | 27 |
| Mirtazapine | Mirtazapine | 39 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 16 |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 12 |
| Fluconazole | Fluconazole | 36 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 12 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | 12 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 28 | 13 |
| Carvedilol | Carvedilol | 28 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Prevident 5000 Sensitive | Sodium Fluoride/Potassium Nit | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Tirosint | Levothyroxine Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Osphena | Ospemifene | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Triamterene | Triamterene | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,786.92 · 30 records | Boston Scientific Corporation | Arikayce, BREZTRI, Cologuard Collection Kit, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, GEMTESA, Korlym, Leqembi, Ozempic, Prolastin-C Liquid, TRINTELLIX, VRAYLAR, WATCHMAN Access System, WATCHMAN FLX, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error